# A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation

> **NCT03955198** · PHASE2 · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 4 (actual)

## Conditions studied

- NSCLC

## Interventions

- **COMBINATION_PRODUCT:** Radiotherapy + durvalumab

## Key facts

- **NCT ID:** NCT03955198
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-27
- **Primary completion:** 2024-08-26
- **Final completion:** 2024-08-26
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03955198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03955198, "A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03955198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*